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Abstract 
The addition of mono-ubiquitin or poly-ubiquitin chain to signaling proteins in response to DNA damage signal is 
thought to be a critical event that facilitates the recognition of DNA damage lesion site, the activation of checkpoint 
function, termination and checkpoint response and the recruitment of DNA repair proteins. Despite the ubiquitin 
modifiers, removal of ubiquitin from the functional proteins by the deubiquitinating enzymes (DUBs) plays an impor-
tant role in orchestrating DNA damage response as well as DNA repair processes. Deregulated ubiquitination and 
deubiquitination could lead to genome instability that in turn causes tumorigenesis. Recent TCGA study has further 
revealed the connection between mutations in alteration of DUBs and various types of tumors. In addition, emerg-
ing drug design based on DUBs provides a new avenue for anti-cancer therapy. In this review, we will summarize the 
role of deubiquitination and specificity of DUBs, and highlight the recent discoveries of DUBs in the modulation of 
ubiquitin-mediated DNA damage response and DNA damage repair. We will furthermore discuss the DUBs involved in 
the tumorigenesis as well as interception of deubiquitination as a novel strategy for anti-cancer therapy.
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Background
Genomic integrity is constantly challenged by DNA 
lesions produced as by-products of normal cellular 
metabolism, DNA replication or induced by radiation 
and toxic environmental chemicals. DNA damage could 
lead to detrimental effects on DNA replication and tran-
scription, ultimately generating mutations and chromo-
somal aberrations that could contribute significantly to 
tumorigenesis. Upon DNA damage a series of guardian 
events occur, including the cellular recognition of DNA 
damage lesion site, initiation and amplification of DNA 
damage signal to activate DNA damage checkpoint func-
tion and activation of various type of DNA damage repair 
pathways are orchestrated by posttranslational modifica-
tion, especially protein ubiquitination and deubiquitina-
tion, which preserve the genomic integrity.
Ubiquitination, a posttranslational modification cova-
lently attaching ubiquitin to targeted proteins, deter-
mines or alters protein’s biological activity, stability or 
subcellular localization. Unlike the proteolytic regulation, 
a variety of DNA damage signaling modules are regu-
lated by non-degrading ubiquitin-chain that result in the 
recruitment of DNA damage proteins to the damage site 
and activation of protein function. Like the balance of 
phosphorylation events by the phosphatases, the ubiquit-
ination is counteracted by deubiquitinases.
Deubiquitinating enzymes (DUBs), proteases that 
reversely modify proteins by removing ubiquitin or 
ubiquitin-like molecules or remodeling ub-chains on 
target proteins, have recently be regarded as crucial 
regulators of both the ubiquitination-mediated degrada-
tion and other functions. Therefore, DUBs have a great 
influence on many biological processes and cellular path-
ways, including DNA damage response and DNA repair 
pathways. Thus, exploration of the in-depth mechanism 
by which DUBs regulate DNA damage response and 
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DNA repair could provide new strategies for anti-cancer 
therapy.
General roles of DUBs and DUBs specificity
Ubiquitination, the process in which ubiquitin (Ub) that 
conjugate ubiquitin to targeted proteins through a cas-
cade composed of E1, E2 and E3 enzymes, plays a vital 
role in multiple biological processes [1]. Ubiquitin con-
tains seven lysine residues in total 76 amino acids and 
can form poly-ubiquitin chains of eight different linkages 
(K6, K11, K27, K29, K33, K48, K63, and Met1), as well as 
mixed and branched chains [2]. Distinct linkage types 
result in different chain conformations and display vari-
ous functions such as protein degradation, localization 
or protein–protein interactions. For instance, protein 
degradation through the ubiquitin–proteasome system is 
mainly mediated by K6, K11, K27, K29, and K48 linked 
polyubiquitin chains [3]. However, K63 polyubiquitin 
chains are mainly contributed in the lysosomal pathway 
and endocytosis, DNA-repair, and signal transduction 
[4]. Besides, linear chains mediate NF-κB and Wnt sign-
aling, cell death and appear to be required for angiogenic 
processes [5]. Single ubiquitin molecule could be conju-
gated to the substrate and is involved in the control of 
endocytosis, intravesicular transport, transcriptional reg-
ulation, DNA replication, and repair [6].
The reversal modification of adding ubiquitin to tar-
geted proteins relies on deubiquitinating enzymes 
(DUBs), which catalytically cleave single Ub or poly-
ubiquitin chains from proteins. The human genome 
encodes approximately 100 potential DUBs which can be 
classified into six families: ubiquitin-specific proteases 
(USPs), ubiquitin COOH-terminal hydrolases (UCHs), 
ovarian tumor proteases (OTUs), Josephins, the JAB1/
MPN/MOV34 family (JAMMs) and motif interacting 
with Ub-containing novel DUB family (MINDYs) [7]. 
USPs, UCHs, OTUs, Josephins and the newly identified 
MINDYs families belong to thiol proteases, while the 
sixth, JAMMs, are Zn2+ metalloproteases [8].
Main roles of DUBs
The mechanism of protein degradation mediated by 
ubiquitin has been studied in depth, meanwhile, growing 
evidence reveals the non-proteolytic roles of ubiquitin 
modification. Here we will summarize the main roles of 
DUBs (Fig. 1).
Counteracting the ubiquitin cascade
Modulating E2 activity
Generally, DUBs could inhibit ubiquitination by interfer-
ing with the formation and the reactivity of the E2-Ub 
intermediate. This is a mechanism that couples the 
opposing activities of the ubiquitination machinery in 
which DUBs maintain and modulate the dynamic bal-
ance of the ubiquitin–proteasome system catalytically or 
non-catalytically.
Ataxin-3, a DUB associated with Machado–Joseph dis-
ease, was reported to reduce the self-ubiquitination of 
parkin, a familiar form of Parkinson disease-associated 
E3 ubiquitin-ligase [9]. Intriguingly, Ataxin-3 is unable 
to remove pre-assembled ub-linkage on Parkin, but can 
regulate the formation of newly assembled Ub conju-
gates on Parkin by interacting with Parkin’s E2 conjugat-
ing enzyme UbcH7 in a Parkin-depend manner [10]. The 
temporary formation of E2-parkin-Ataxin-3 complex 
contributes to the stabilization of E2 and Parkin inter-
action, impeding the dissociation of the uncharged E2 
which can be recharged by E1, meanwhile diverting the 
Ub from the E2-Ub thioester conjugate onto Ataxin-3 
itself, and away from parkin.
OTUB1 has recently emerged as a unique DUB that 
binds and inhibits several classes of E2s, including Ubc13 
and UbcH5s, without reflecting DUB activity per se [11]. 
OTUB1 was shown to directly bind the Ub thiolester 
Ubc13 intermediate (Ubc13 ~ Ub). The N-terminal resi-
dues of the OTU domain in OTUB1 are required for 
binding to UBC13 ~ Ub and this interaction is facilitated 
by the binding of a free Ub to a second site in OTUB1, 
resulting in allosteric change in the OTU domain and the 
formation of a ubiquitin-binding helix in the N-terminus 
which increase its affinity for UBC13-Ub. By binding to 
OTUB1, UBC13-Ub could neither transfer ubiquitin nor 
bind to E3 ligase. Similarly, by predominately binding to 
“charged” UbcH5b, OTUB1 was concluded to function as 
an E2 inhibitor, reflected in preventing the auto-ubiquit-
ination of the E3 ligase TRAF6.
USP7 is a deubiquitinating enzyme found in all eukary-
otes that catalyzes the removal of ubiquitin from specific 
target proteins such as Mdm2, ICP0, and p53 [12]. USP7 
could interact and forms a complex with an E2 ubiqui-
tin conjugation enzyme, UbE2E1, requiring the N-ter-
minal ASTS sequence of UbE2E1. As a result of binding, 
UbE2E1-mediated ubiquitination was attenuated via 
the ASTS motif within its N-terminal extension and the 
catalytic domain of USP7. Inactivation or disruption of 
the interaction between USP7 and UbE2E1 could lead to 
UbE2E1 destabilization as well [13].
Counteracting E3s
Many DUBs are associated with E3 ligases in pairs or 
complexes. DUBs co-regulate with E3 ligase partner to 
fine-tune the ubiquitin loading and removal of target 
proteins, which even refer to the E3 ligases when they 
could be self-ubiquitylated. The DUBs could be treated as 
prey when they are ubiquitinated by its E3 ligase partner 
or others.
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USP10 is one of DUBs which regulate the stability of 
p53 both under physiological condition and in response 
to DNA damage with its E3 partner Mdm2. The main 
role of USP10 is to maintain the stable level of p53 in 
cytosol [14]. However, following DNA damage, part of 
USP10 translocate into nucleus to deubiquitylate p53 
and thus boost p53 activation. With another E3 ligase 
partner Huwe1, USP10 appears to modulate the degra-
dation of TATA-binding protein (TBP) during myogen-
esis [15]. In myoblasts, Huwe1 and USP10 co-operate 
to keep the homeostasis of TBP. Upon muscle differ-
entiation stimulation, increased Huwe1 and declined 
USP10 lead to TBP ubiquitination and its proteasomal 
degradation.
A typical characteristic of E3 ligases is the ability of 
self-ubiquitination. Many E3 ligases catalyze their own 
ubiquitination in intermolecular or intramolecular mode, 
leading to degradation or non-proteolytic outcomes such 
as activity regulation. DUBs can reverse these ubiquitina-
tion events, modulating E3 ligase stability or activity and 
dynamically controlling the abundance of downstream 
substrates.
USP15 deubiquitylates autoubiquitinated Mdm2 to 
regulate p53 function and cancer-cell survival, while the 
stabilized Mdm2 negatively regulates T cell activation 
by targeting the transcription factor NFATc2 [16]. USP7 
deubiquitinates ubiquitinated (by itself or external ligase 
such as E6AP) RING1B ligase of the polycomb complex 
[17]. Ataxin-3 interacts with monoubiquitinated CHIP 
and limits the length of the poly-ubiquitin chain of the 
target protein attached by CHIP. After this fine-tuned 
ubiquitylation is accomplished, Ataxin-3 removes the 
Fig. 1 Main roles of DUBs. Deubiquitination is involved in counteracting the ubiquitin cascade, including inhibiting E2 ubiquitin conjugating 
enzymes and E3 ligases. Proteasome related DUBs help to prevent degradation of ubiquitin chains of proteins treated. Lysosome-associated DUBs 
play crucial roles in receptor degradation and recycling. Alternatively, DUBs can remove or edit ubiquitin chains to change non-degradation ubiq-
uitin signals. After releasing ubiquitin chains from proteins, DUBs are also responsible for the generation of free ubiquitin from ubiquitin precursors 
and the release of ubiquitin from unanchored isopeptide-linked ubiquitin chains into ubiquitin pool
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single ub from CHIP to terminate their interaction [18]. 
SMURF1, a Nedd4 family of HECT ubiquitin ligases, is 
self-ubiquitinated through its intrinsic HECT E3 ligase 
activity and marked a degradation signal, which is antag-
onized by USP9X via interacting with SMURF1 through 
the second WW domain of SMURF1 and the carboxyl 
terminus of USP9X [19].
Mdm2/USP7 and Ro52/USP4 are two E3/DUB pairs 
which are transregulated by each other. [20, 21]. When 
the substrate proteins are not required for degradation, 
the E3 ligases will be auto-ubiquitylated and their DUB 
partners are responsible for their stabilization. Con-
versely, USP4 can be ubiquitylated by Ro52 and subse-
quently degraded.
Assisting degradation machinery
Proteasomal route related DUBs
POH1/PSMD14/Rpn11 is a constitutive stoichiomet-
ric component in the 26S proteasome “cap”-19S regula-
tory particle (RP) and is essential for the RP’s assembly. 
POH1, belonging to metalloproteases subfamily JAMMs, 
is responsible for the hydrolysis of ub-chains before pro-
teins are unfolded and degraded [22]. However, before 
deubiquitination of the substrate by POH1, two other 
DUBs UCH37 and Ubp6/USP14 antagonize protein 
degradation by trimming ubiquitin chains from the dis-
tal end of the chain leading to a decreased affinity of 
the protein for the proteasome [23, 24]. Unlike UCH37, 
USP14 not only removes single ubiquitin from Ub-chain 
but also bi- or tri-Ub, it can also preferentially remove 
ubiquitin chains en bloc from substrates with multiple 
ubiquitinated sites [25]. Besides, Ubp6 was also shown to 
stabilize the substrate via allosteric interference with the 
binding of the incoming substrate with the proteasome 
[24].
Endocytic pathway related DUBs
Research in endocytic pathways, especially the largely 
focused lysosomal degradation of cell-surface receptors, 
pointed out two DUBs, AMSH and USP8/UBPY [26, 
27]. These two DUBs both localize to sorting endosomes 
through interactions with the endosomal sorting com-
plex required for transport (ESCRT) components of 
the ESCRT machinery, mainly the ESCRT-0 compo-
nent signal transducing adaptor molecule  (STAM) and 
the ESCRT-III charged multivesicular body proteins 
(CHMPs) [28]. While both K63-specific DUB AMSH and 
non-ub-chain specific USP8 balance the receptor degra-
dation and recycling, exhibiting negative regulation of 
lysosomal sorting, the roles of AMSH and USP8 are wor-
thy of digging at depth [29]. AMSH and USP8 showed a 
positive role in the downregulation of protease-activated 
receptor 2 and additionally, USP8 exhibits pleiotropic 
effects considering its regulatory role in ESCRT-0 and 
receptors per se [30, 31].
Maintaining ubiquitin homeostasis
Maintaining ubiquitin homeostasis includes the genera-
tion of Ub precursors from encoded genes, the trim of 
Ub precursors to free Ubs, the disassembly of polyubiq-
uitin chains from proteins, and the recovery of Ub from 
chains and other inadvertently trapped Ub derivatives.
In mammals, four Ub precursors encoded by differ-
ent genes are UBA52, UBA80, L40 and S27A, of which 
the former two are C-terminal single Ub fused to a ribo-
somal protein (Ub-RPs), and the rest two are Ub poly-
mers linked in “a head to tail” mode followed by various 
amino acids in C-terminus (polyUbs). USP5 and Otulin/
Gumby/FAM105b preferentially catalyze polyUbs both 
co- and post-translationally, while UCHL3, USP9X and 
USP7 are found to be the main enzymes of Ub-RPs in 
charge in a form of post-translational modification [32]. 
USP5 is the major DUB which releases ubiquitin from 
unanchored isopeptide-linked ubiquitin chains, through 
the ZnF-UBP domain that recognizes the free C-termi-




The primary Ub binding site that DUB catalytic domains 
possess has substantial interactions with the distal Ub in 
a poly-ub chain mainly through Ile44 patch, with differ-
ent interacting surfaces among DUB subfamilies [34]. The 
C-terminus of the distal Ub forms a firmly held stretch 
from the binding site into the DUB catalytic center, allows 
DUBs to catalyze and distinguish Ub from other ubiqui-
tin-like molecules (ULMs). The C-terminal sequence of 
Ub (Leu71, Arg72, Leu73, Arg74, Gly75, Gly76), is what 
makes it different from those of ULMs, and among these 
six amino acids, Arg74 and Gly75 are crucial for ubiqui-
tin recognition by DUBs [35]. Due to possessing the same 
C-terminal sequence of Ub, a ULM interferon-stimulated 
gene 15 (ISG15) could be recognized by some DUBs [36]. 
However, USP18 can only cleave a linear fusion of ISG15 
but not of ubiquitin, suggest the existence of different 
specify levels of DUBs [37].
Linkage preference
As the different conformations of diverse linkage types 
and chain lengths determine the Ub signals and thereby 
the fate of target proteins, it is not surprising that some 
DUBs have linkage specificity in the deubiquitylation 
reaction (Fig.  2). Most OTU or JAMM protease mem-
bers show inherent specificity. For instance, OTUB1 
has a striking specificity for K48-linked chains thus 
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protecting the substrates from degradation and AMSH, 
AMSH-LP and BRCC3 prefer to cleave non-degradative 
K63-chains, while the OTULIN preferentially cleaves 
linear Ub chains [11, 38, 39]. On the other hand, other 
DUBs like USP family members display little linkage 
selectivity [40].
Positioning specificity (exo‑/endo‑/mono‑DUB)
Ubiquitin chains can be cleaved from the distal part (exo) 
or internally (endo). USP14, as mentioned above, cleaves 
K48-linked chains from the distal end only (exo-activity), 
generating mono-ubiquitin [41]. In comparison, endo-
cleavage could be observed in those non-degradative ub-
chains by DUBs such as CYLD and AMSH-LP [42, 43]. 
The positioning specificity could be explained based on 
DUB’s structure difference. USP14 encompasses a finger 
subdomain which contacts up to 40% of the distal ubiq-
uitin and blocks access to K48 or K63, allowing USP14 
to bind to the distal end of an ubiquitin chain, but not 
to internal linkages. However, CYLD, due to the lack 
of the fingers subdomain, allows access to K63 [44, 45]. 
The cleavage of the first Ub molecule of a poly-ub chain 
requires DUBs with lower specificity of ub-chain link-
age such as UCH subfamily members UCHL3, consid-
ering its role in processing precursor Ub [32]. Similarly, 
processing of monoubiquitin also requires non-specific 
DUBs which could adjust in their proximal binding site 
and also recognize the protein substrate [46]. The change 
of one chain type to another type, which would detour 
the fate of the substrate, would be easier for the protein 
with a proximal Ub left on.
Substrate protein recognition
Apart from linkage and positioning specificity, another 
feature of DUBs is substrate selectivity. As a conse-
quence, many DUBs are found associated with substrates 
directly through the binding domains, or indirectly via 
adaptors and scaffolds.
Some DUBs display affinity for the ubiquitinated pro-
tein directly through their protein interaction domains. 
Crystal structure analysis showed that USP7 binds to 
its substrate p53 and its inhibitory interactor Epstein–
Barr nuclear antigen 1 (EBNA1) protein through the 
same pocket but the former binding partner p53 exhibit 
weaker contacts with USP7 [47, 48]. Further functional 
studies indicated that EBNA1 binding to USP7 inhibits 
its interaction of p53 and protects cells from apoptotic 
challenge by lowering p53 levels [12].
Adaptors or scaffolds could facilitate the association 
between DUBs and substrates. Adaptor protein p62 
binds to CYLD and recruits it to TRAF6 [49]. NEMO, 
another potential adaptor of CYLD, directly binds CYLD 
and associates with various IKK regulators, such as RIP1 
and TRAF2 [50]. OTUD4, rather than being a DUB, acts 
as a scaffold for USP7 and USP9X, two DUBs that act 
directly on the DNA demethylases such as ALKBH2 and 
ALKBH3 [51]. Functionally, the loss of OTUD4, USP7, 
or USP9X in tumor cells leads to significantly increased 
Fig. 2 Specificity of DUBs. The recognition and cleavage of ubiquitin chains requires multiple layers of specificity, including the distinguish of 
ubiquitin from ubiquitin-like molecules, the ubiquitin linkage preference, the position of cleavage site and the recognition of targeted proteins with 
or without the assistance of adaptors or scaffolds
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sensitivity to alkylating agents. The translation initiation 
factor 3f (EIF3F) is recruited to activate Notch on endo-
cytic vesicles by the Deltex1 serving as a bridging factor. 
Notch couldn’t be processed by the gamma-secretase 
until it’s deubiquitinated by EIF3F [52].
DUBs and genomic integrity
DNA damage response main components and signaling
In the face of the continuous threat from both exogenous 
and endogenous genotoxic insults, cells generate a com-
plex network to maintain the genomic integrity, which 
is vital for various aspects of organism physiology, rang-
ing from homeostasis to cancer prevention. DNA dam-
age response (DDR), which includes surveillance proteins 
monitoring and detecting DNA damage, activating cell 
cycle checkpoints and ensure the effective DNA damage 
repair [53]. The checkpoint response can repair the dam-
aged DNA before it passes on through mitosis, or make 
the decision of apoptosis if the damage is too difficult 
to repair [54]. DDR coordinates DNA repair with vital 
cellular functions to determine the fate of the cell after 
DNA damage [55]. As the fact that ubiquitination plays a 
prominent role in DDR, it could be expected that DUBs 
also serve as crucial regulators in DDR and DNA repair 
pathways (Fig. 3).
Various types of DNA lesions including DNA single- 
and double-strand breaks (SSBs and DSBs) are gener-
ated all the time in cells. Sensors such as MRN complex, 
Ku70/Ku80 heterodimer (KU) and PARPs are activated 
in response to DSBs (the former two) and SSBs [58]. 
FANCM, act as the sensor of interstrand crosslink (ICL)-
induced checkpoint response [59]. RPA binds to regions of 
exposed single-stranded DNA (ssDNA) in lesion area and 
the following events are the recruitment of ATM and ATR-
ATRIP mediated by MRN and RPA respectively, the sub-
sequent activation of the downstream pathways [60]. KU 
recruits DNA-PKcs to form the catalytically active DNA-
PK holoenzyme in the canonical non-homologous end 
joining (NHEJ) repair pathway [61]. On the other hand, 
MRN initiates homologous recombination (HR) [62].
Once activated, the cell-cycle checkpoint kinases CHK1 
and CHK2 trigger the DNA damage signaling cascade to 
extend, gathering downstream effectors such as the p53 
or the CDC25 and WEE1 [63]. Consequently, cyclin-
dependent kinase (CDK) activity is inhibited, stalling cell 
cycle progression from G1 to S (the G1/S checkpoint) or 
from G2 to M phase (the G2/M checkpoint) [64]. The 
DDR thus masterminds a variety of events including the 
altered transcriptional program and the contemporarily 
arrested cell cycle, thereby facilitating repair of the DNA 
lesions. When DNA damage is too severe to be repaired, 
the fate of the damaged cell is apoptosis or senescence 
[65].
USP4 was found to interact with the DNA end resec-
tion factor CtIP and MRN complex via its C-terminal 
insert region and promoting the binding of CtIP/MRN by 
contracting its own ubiquitylation, which interfered with 
CtIP and MRN binding, thus impairing DNA end resec-
tion and HR [56]. UCH37, as previously mentioned, is a 
19S regulatory particle related DUB as well as a compo-
nent of INO80 chromatin-remodeling complex which 
is known to directly associate with DSB ends and is 
required for DSB end resection and overall DSB repair 
[66, 67]. Interestingly, Ku70 was found to function as a 
DUB to stabilize Mcl-1 by directly interacting with Mcl-1 
via its C-terminus, which is required and sufficient for 
deubiquitination and stabilization of Mcl-1, leading to 
suppression of apoptosis [68].
USP1 and USP7 are reported to be involved in deu-
biquitination and stabilization of Chk1 [69, 70]. USP7 
was also shown to regulate other DDR proteins such 
as Claspin, an adaptor protein activated by Chk1 in the 
ATR–Chk1 pathway [71]. Importantly, the USP7 cata-
lytic mutant is in a mono-ubiquitinated form, suggesting 
it is self-regulated by its hydrolase feature. Addition-
ally, USP29 and USP20 were found to be other DUBs for 
Claspin, [72, 73].
The E3 ligase PIRH2 interacts with and ubiquitinates 
CHK2 dependent on its phosphorylation status. USP28 
forms a complex with PIRH2 and CHK2 and antagonizes 
PIRH2-mediated polyubiquitylation and proteasomal 
degradation of CHK2 [74].
The ubiquitin modification of p53 is much compli-
cated than that of other DDR components. Several 
E3 ligases target p53, of which Mdm2 plays a major 
role both in controlling basal levels of p53 in normal 
unstressed cells and in response to stress conditions 
[75]. Other E3 ubiquitin ligases identified include COP1, 
Pirh2, ARF-BP1, MSL2, and Parc [76–78]. On the other 
hands, several deubiquitinating enzymes to date have 
been identified targeting p53. These DUBs can target 
p53 directly or indirectly by regulating the E3 ligase 
Mdm2. USP7 was the first DUB identified to target p53 
and Mdm2 for deubiquitination [79]. USP2a specifically 
deubiquitinates Mdm2 and MdmX [80]. In contrast to 
USP7 and USP2a, USP10 specifically deubiquitinate 
p53 because knockdown of USP10 in HCT116 p53−/− 
cells does not cause Mdm2 reduction [14]. Importantly, 
USP10 can be phosphorylated by the ATM kinase, lead-
ing to its stabilization and nuclear translocation. Simi-
larly, USP42 is a p53-specific deubiquitinase and plays 
a role in DNA damage-induced p53 stabilization [81]. 
USP24 is required for p53 stabilization in unstressed 
cells, as well as for p53 stabilization and PUMA activa-
tion after DNA damage [82]. Both OTUD5 and USP29 
are required to be p53-dependent transcriptionally 
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induced to stabilize p53 in response to DNA damage 
stress [83, 84]. Additionally, USP5 indirectly regulates 
levels of p53, while UCHL1 forms a complex with p53/
p14 (ARF)/Mdm2 p53 binding protein homolog in the 
mouse [85, 86]. Recently, CYLD was shown to promote 
DNA damage-induced p53 stabilization and activa-
tion in epithelial cells and inhibit chemical carcinogen-
induced intestinal and skin tumorigenesis [87]. Taken 
together, the varying actions of these deubiquitinases 
allow for dynamic p53 regulation in a context-depend-
ent manner.
DUB3/USP17 mediates deubiquitination of CDC25A, 
preventing CDC25A degradation by the proteasome 
during the G1/S and G2/M phases promoting cell-cycle 
progression [57]. USP50 was identified as an interacting 
partner of HSP90. In response to DNA damage, USP50 
accumulates in the nucleus and may act through an 
HSP90-dependent mechanism to counteract CDC25B 
mitotic inducing activity and prevent Wee1 degradation, 
thereby repressing entry into mitosis following activation 
of the DNA damage checkpoint [88].
DNA damage repair
DNA may be modified resulting from numerous geno-
toxic agents such as ultraviolet in the form of single-
strand breaks (SSBs) and/or double-strand breaks (DSBs) 
[89]. UV-induced damage also can result in the produc-
tion of pyrimidine dimers and the formation of cova-
lent cross-links [90]. Rapid and well-organized repair 
machinery composed of sensors and repair proteins are 
responsible for removing these lesions thus maintaining 
genomic integrity. Major repair pathways include base 
excision repair (BER), mismatch repair (MMR), nucleo-
tide excision repair (NER), homologous recombination 
(HR), non-homologous end joining (NHEJ), and transle-
sion synthesis (TLS) (Fig. 4) [91].
Single strand break
Since only one of the double strands of DNA is defec-
tive, the other strand could be used as a template. Taking 
advantage of this situation, several excision repair mech-
anisms exist, among which the BER repairs small base 
lesions while NER deals with bulky helix-distorting lesions.
Fig. 3 DUBs that modulate the key factors of the DNA damage response leading to different cell fates. USP4 was found to interact with one of 
the DNA damage sensors MRN complex and the DNA end resection factor CtIP and interfered with CtIP and MRN binding, thus impairing DNA 
end resection and HR [56]. USP1 and USP7 are reported to be involved in deubiquitination and stabilization of Chk1. USP28 forms a complex with 
PIRH2 and CHK2 and antagonizes PIRH2-mediated polyubiquitylation and proteasomal degradation of CHK2. Several deubiquitinating enzymes to 
date have been identified targeting p53 which will be discussed in this review. These DUBs can target p53 directly or indirectly by regulating the 
E3 ligase Mdm2. DUB3 mediates deubiquitination of CDC25A, preventing CDC25A degradation during the G1/S and G2/M phases, promoting cell-
cycle progression [57]
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The initial step of BER is performed by DNA glycosy-
lases, which scan along the DNA backbone to recognize 
and remove defective bases and form apurinic/apyrimi-
dinic (AP) sites. These AP sites are then processed by AP 
endonuclease 1 (APE1) and DNA polymerase β (Pol β) to 
leave a single strand break and synthesize a new, no-error 
nucleotide. The final nick-sealing work is accomplished 
by DNA ligase IIIα (Lig III) along with its cofactor X-ray 
cross-complementing protein 1 (XRCC1) in short-patch 
BER. DNA ligase I ligates the break in long-patch BER 
[92]. Besides, endonuclease VIII-like proteins (NEIL1-3) 
have been identified as new human DNA glycosylases, 
with similar mistake elimination function but different 
lesion preferences [93].
USP47 is the major enzyme involved in deubiqui-
tylation of Pol β. USP47 stabilizes the cytoplasmic Pol β 
which will relocate to the nucleus in DNA damage path-
way. Knockdown of USP47 decreased the level of Pol β 
which defect the BER pathway, leading to accumulation 
of DNA strand breaks induced by DNA damaging agents 
[94].
NER repairs bulky DNA base adducts and ultraviolet 
light-induced lesions. NER can be divided into two main 
pathways based on the damage recognition mechanism: 
global genome repair (GG-NER) and transcription-cou-
pled repair (TC-NER). The two pathways share the same 
processes in incision, repair, and ligation. DDB1-DDB2/
XPE and XPC/RAD23 complexes are responsible for 
damage detection in GG-NER [95].
DDB2, associates with DDB1, to recruit XPC to chro-
matin, and also facilitates the recruitment of cullin 
4A/B-RING ubiquitin ligases which ubiquitinate various 
acceptor proteins including DDB2 and XPC [96]. When 
RNA polymerase II (RNAP II) stalls upon encounter-
ing a DNA lesion during transcription, TC-NER is acti-
vated and RNAP II is ubiquitinated and dislocated from 
chromatin. Recognition of damage is dependent on CSB 
(ERCC6), which associates with RNAP II and recruits 
CSA (ERCC8) to the lesions, the latter serves as E3 
ligase of CSB in the CSA-CUL4A complex [97]. Revers-
ibly, USP7 regulates NER targeting XPC protein and 
preventing XPC protein from undergoing UV-induced 
and VCP/p97 regulated proteolysis [98]. Furthermore, 
USP7 and UVSSA protein couple and counteract CSA-
dependent degradation of CSB to allow sufficient time 
for CSB to perform its function in TC-NER when RNAP 
II is remodeling [99]. Proteolysis of damage-induced 
RNAP II is tightly regulated by both E3 ligases and DUB. 
Fig. 4 DUBs that regulate major DNA damage repair pathways, including the modification of histones (with green outer glow), base excision repair 
(with yellow outer glow), nucleotide excision repair (with violet outer glow), homologous recombination and non-homologous end joining (with pink 
outer glow), and inter-strand crosslink damage repair including Fanconi anemia pathways and translesion synthesis (with grey outer glow)
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In yeast, it has been shown that the degradation associ-
ated K48-linked ub chain is generated in 3 steps. Rsp5 
E3 (NEDD4 in mammals) catalyzes K63-linked ub chain 
which is trimmed by a DUB Ubp2 resulting in the mono-
ubiquitination of RNAP II, prompting a second E3 ligase 
Elongin/Cullin 3 complex to generate K48-linked ub 
chains [100].
Double‑strand break
HR and NHEJ are two major DSB repair pathways. HR 
repair generates error-free strands by acquiring genetic 
information from sister chromatids, whereas NHEJ may 
lead to mutagenesis by ligating two broken ends directly, 
in which process the loss of the nucleotide in DSB may 
cause deletion and joining of non matching ends may 
cause insertions or translocations [101]. Increasing evi-
dence has demonstrated the important role of DUBs in 
mediating the DSB repair pathways.
Post-translational modifications of histone, espe-
cially phosphorylation of H2AX by ATM and sequential 
recruitment of MDC1, is the key initial event in DSB 
repair [102]. Phosphorylated MDC1 by ATM recruits E3 
ligase RNF8 to add K63-ub chains to H1, forming a bind-
ing site for RNF168 to H1 [103]. Then RNF168 is ready to 
induce K63-/K27-ubiquitination on H2A, which in turn 
enhance the recruitment of RNF168 [104]. Besides, ubiq-
uitination of H2B by RNF20–RNF40 is demonstrated 
to be crucial in response to DSB, as this ubiquitination 
event is important for the formation of open and bio-
chemically accessible chromatin fiber that is conducive to 
DNA repair [105]. H1 and H2A may not be the respec-
tive substrates for RNF8 and RNF168 at DSB lesions. 
Recent studies have revealed that the polycomb molecule 
L3MBTL1 and the lysine demethylase JMJD2A are also 
substrates of RNF8 [106, 107]. RAP80 is a key factor at 
ubiquitinated structures on chromatin surrounding DSB 
sites. RAP80 facilitates the recruitment of BRCA1 to DSB 
sites as a scaffold molecule but the BRCA1-RAP80 com-
plex limits nuclease accessibility to DSBs, thus preventing 
excessive end resection and potentially deleterious HR 
[108]. RAP80 also helps to recruit BRCC36, which regu-
lates the NHEJ repair [109]. 53BP1, a key factor in NHEJ 
pathway, interacts tightly with nucleosomes containing 
both H4K20me2 and RNF168-dependent ubiquitinated 
histone H2A [110]. 53BP1 promotes the NHEJ pathway 
via the inhibition of BRCA1 recruitment, the recruitment 
of RIF1 and REV7 (anti-DNA end resection factors) and 
the recruitment of Artemis nuclease through PTIP [111].
DUBs of H2A and H2AX are partially shared. USP3, 
Dub3, USP11 and BAP1 show their DUB ability in 
H2AX-ub, while USP3, USP44, USP26, USP37, BAP1, 
USP16, and MYSM1 are DUBs which remove ubiq-
uitin or ubiquitin chains from H2A. USP44 also can 
deubiquitinate H2B-Ub [112–115]. On the other hand, 
the stability of RNF168 is sustained by DUB USP34 
and USP7. Recently, OTUB2 was suggested to target 
L3MBTL1 and K 63-linked ubiquitin chains to counter-
act the function of RNF8 and thus enhanced recruitment 
of 53BP1 and RAP80 [116]. USP11 was shown to interact 
with and deubiquitinates BRCA2 and as well counteracts 
RNF4-induced SUMO-ubiquitin hybrid chains, suggest-
ing the pleiotropic roles at DSBs sites [117]. USP28 was 
shown to bind 53BP1, but only minor DDR defects were 
observed in USP28-depleted cells, suggesting its minor 
role in DSB repair. [118]. UCH37 was reported to regu-
late DSB resection and repair by HR pathway through 
stabilizing nuclear factor related to Kappa-B-binding 
protein (NFRKB) [66].
There are some DUBs found to be crucial in remov-
ing ub/ub-chains at DSB sites without clear substrates 
such as BRCC36, POH1, and USP5, which antagonize 
the K63-linked polyubiquitin conjugates at damage sites 
[109, 119].
Interstrand crosslink
ICLs are thought to be a highly toxic type of DNA dam-
age which prevent transcription and replication. Defec-
tive repair of DNA of ICLs is a key feature of Fanconi 
anemia (FA). FA pathway is now thought to involve the 
coordination of HR, NER and TLS. There are currently 
15 known genes (FANCA to FANCP) whose bi-allelic 
mutations yield FA [120].
Central to FA pathway is the monoubiquitination of 
FANCD2 (K-561) and FANCI (K-523) by the FA core 
subunit FANCL [121, 122]. This monoubiquitination 
is stimulated by DNA damage and it sends the signal 
to other FA proteins such as nucleases FANCP (SLX4) 
and FANCQ (XPF), and downstream repair factors like 
FANCJ (BRIP), FANCN (PALB2), FANCD1 (BRCA2), 
and FANCO (RAD51C) [120].
USP1 was one of the first ubiquitin hydrolases charac-
terized as a key player in ICL repair pathways. USP1, the 
major DUB of FANCD2 and FANCI, inactivates these 
two proteins mediated by the USP1-activating factor 
UAF1 once DNA damage repair is finished [123].
DUBs indeed affect many other DNA damage repair 
processes, taking PCNA as an example. Under rep-
lication stress, PCNA is monoubiquitinated by the 
UBE2B-RAD18 and then recruits and activates poten-
tial error-prone DNA polymerases. Poly-ubiquitination 
of PCNA induced by E2 complex UBE2N–UBE2V2 and 
the E3 ligases HLTF, RNF8 and SHPRH makes it involved 
in an error-free template switching pathway [124]. USP1 
and USP7 are identified as a DUB of mono-ubiquitinated 
PCNA acting in different cell cycle phases (S-phase 
and interphase respectively) [46, 125]. Since PCNA is 
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reported to associate with Epstein–Barr virus (EBV) 
DNA during its replication, an EBV DUB encoded by 
BPLF1 was found to target ubiquitinated PCNA and dis-
rupts TLS [126].
DUBs involved in diseases and DUBs targeting 
therapeutics
Growing evidence indicates germline and somatic muta-
tions, as well as expression frequency alterations of 
DUBs, are correlated with human disease, ranging from 
immune diseases to many human cancers.
DUBs and diseases
Mutations and deletions in CYLD have been reported 
in Brooke-Spiegler syndrome (BSS), familial trichoepi-
thelioma and malignant transformation [127]. Mutated 
CYLD disrupted its inhibitory function on NF-kB and 
HDAC pathways, resulting in the activation of MYB, 
which plays a vital role in the biology of cylindroma 
either sporadic or emerged with BSS [128]. Additionally, 
CYLD has also be linked to immune response through its 
regulation on Tak1 with E3 ligase Itch, leading to the deg-
radation of Tak1 resulting in the termination of inflam-
matory necrosis factor signaling [129]. A20 is another 
negative regulator of NF-kB pathway. A number of stud-
ies have reported the deletions or mutations of TNFAIP3 
(encoding gene of A20) in lymphomas such as marginal 
zone lymphoma and Non-Hodgkin’s lymphoma, indicat-
ing A20 as a tumor suppressor and immune regulator 
[130]. Recently, high penetrance heterozygous germline 
mutations in TNFAIP3 were considered as the cause of 
an auto-immune related syndrome Haplo insufficiency of 
A20 (HA20), displaying early-onset systemic inflamma-
tion, arthralgia/arthritis, oral/genital ulcers and ocular 
inflammation. Mutated A20 results in truncated proteins 
which is defective in inhibit NF-kB pathway, leading to an 
increased expression of NF-κB-mediated proinflamma-
tory cytokines [131]. BAP1, as mentioned above, could 
remove ubiquitin from H2A in the complex with ASXL1 
[132]. However, recent research revealed a new mecha-
nism of loss of BAP1 contributing to tumorigenesis. By 
targeting atypical polycomb protein L3MBTL2, BAP1 
interacts with and stabilizes L3MBTL2, co-occupying and 
maintaining H4K20me1 at target gene loci, such as EZH2 
locus. Loss of BAP1 leads to reduced L3MBTL2 stability 
and increased EZH2 transcriptional output in mesothe-
lioma [133]. USP8 gene somatic mutations are found in 
corticotroph adenomas, which results in pituitary cor-
ticotroph adenomas hypersecreting adrenocorticotro-
pin (ACTH) and is the major cause of Cushing’s disease. 
Mutated USP8 protein is truncated due to the loss of 
binding site for 14-3-3 protein and gains a higher DUB 
activity. This leads to increased recycling of its substrate 
EGFR, which accumulates on plasma membrane and 
stimulates Pomc gene transcription and increase plasma 
ACTH levels [134].
Numbers of DUBs are associated with tumors by their 
alteration in protein expression. For instance, increased 
expression level of OTUD6B, UCH37, VCPIP1, USP7 
and COPS5 are detected in breast cancer [135]. USP6 is 
considered as an oncogenic protein and overexpressed 
in primary aneurysmal bone cyst (ABC) and nodular 
fasciitis by chromosome translocation, and forms fusion 
proteins with CDH11, TRAP150, ZNF9, OMD, and 
COL1A1, which result in promoter swapping and tran-
scriptional up-regulation [136]. However, roles of some 
DUBs are poles apart in different tumor types. In ovar-
ian and prostate carcinoma, USP2 protein is upregulated, 
whereas in colon cancer, USP2 expression is downregu-
lated [137].
Therapeutics targeting DUBs
Specific mechanisms of deubiquitinating enzymes in 
various diseases have been described. Research should 
be concentrated on discovering an inhibitor on DUB’s 
enzyme activity or antagonist which binds the substrates 
for therapy of cancer and other diseases (Table 1).
DUB inhibition by compounds containing Michael 
acceptors
Compounds containing Michael acceptors such as α, 
β-unsaturated ketones have the inhibitory effect on some 
of cysteine DUBs due to the fact that they can potentially 
form covalent adducts with free thiols in the active site 
[138]. Cyclopentenone prostaglandins (PGs) of the PGJ2 
class, chalcone compounds and other compounds con-
taining Michael acceptors will be discussed here.
UCHL3 was found to be inhibited by Δ12-PGJ2 and 
UCHL1 by 15Δ-PGJ2 [139]. Chalcone compounds G5 
has a broad inhibitory spectrum, whereas another chal-
cone compounds b-AP15 and its analogue VLX1570 
are relatively specific to USP14 and UCH37 [140, 141]. 
USP14 and UCH37, are also inhibited by curcumin ana-
logue AC17 [142]. UCHL1, UCHL3, USP2 and USP8 
were found to be inhibited by AM146, RA-9, and RA-14 
which did not inhibit Ataxin-3, A20, BAP1, Otubain 1 
or USP7 [143]. WP1130 acts as a partially selective DUB 
inhibitor for USP9x, USP5, USP14, and UCH37, result-
ing in downregulation of antiapoptotic and upregulation 
of proapoptotic proteins, such as MCL-1 and p53 [144]. 
Eeyarestatin-1 (Eer1) was identified to inhibit p97/VCP-
associated DUB activity such as that of Ataxin-3 [145].
Other small molecule DUB inhibitors
Due to the multifaceted roles of USP7, many inhibitors 
have been developed targeting USP7, such as P022077, 
Page 11 of 15He et al. Cell Biosci  (2016) 6:62 
HBX 41,108, HBX-19,818, HBX-28,258, P5091, Cpd 
14 and P22077, in which the latter two molecules also 
inhibit USP47 [146–151]. A small molecule IU1 has been 
described as specific inhibitor of USP14, only binding the 
activated USP14 [139]. LDN-57444 is an isatin O-acyl 
oxime reported to selectively inhibit UCHL1 in a revers-
ible, competitive, and active site-directed manner [152]. 
Compared to LDN-57444, LDN91946, 3-Amino-2-keto-
7H-thieno [2, 3-b] pyridin-6-one derivative, was discov-
ered as moderately potent, non-competitive inhibitors 
of UCHL1 [153]. Clinical drugs for treating other dis-
eases previously, were found as DUB inhibitors. Pimoz-
ide (an anti-psychotic drug) was identified as inhibitors 
of USP1, and auranofin (a rheumatoid arthritis drug) is 
a proteasome-associated DUB inhibitor [154, 155]. Bene-
fiting from high-throughput screening studies, LS1 as an 
UCHL3 inhibitor and PR-619 as a general DUB enzyme 
inhibitor [156, 157]. Interestingly, the mitochondria-
localized DUB USP30 was found to be inhibited by a dit-
erpenoid derivative 15-oxospiramilactone (S3), leading to 
the increased Mfn1/2 proteins which promote mitochon-
drial fusion [158].
Of  ~100 DUBs, only several DUBs have been investi-
gated for their structures despite identification of a vari-
ety of substrates for various DUBs, providing a rationale 
to open the way for designing small inhibitor molecules. 
‘To date only a few of DUB inhibitors such as VLX1570 
are in clinical trials for tumor therapy. And no DUB 
inhibitor is approved for clinical use. Therefore, much 
work is still required to be accomplished to validate and 
develop them to the clinic.
Conclusion
While the impact of DUBs in the regulation of biologi-
cal function and human diseases have attracted attention 
in the field for a decade, there are still quite a few aspects 
that have not been elucidated. Recent systematic screen-
ing of DUBs in regulating various cellular processes leads 
to diverse landscape of DUBs in regulating different path-
ways. An interesting puzzle needs to be explained is the 
observation of DUB substrates. At the biochemical level, 
how the substrate specificity is established for the limited 
100 DUBs to face over thousands targeting proteins needs 
to be understood. Recently, some new findings enhance 
our knowledge regarding how DUBs interacts with the 
ubiquitin cascade. Despite the simple view of removal of 
ubiquitin chain from the substrate, it has been demon-
strated that DUBs could modulate the activity of ubiqui-
tin conjugating enzyme and directly counteract E3 ligase 
activity as well as to assist degradation machinery. Nev-
ertheless, a better classification of 100 DUBs and their 
mechanism of counteracting ubiquitin cascade needs to be 
done. Other than conventional biochemical and cell bio-
logical dissection of the role of DUBs, more sophisticated 
protein structural studies could enhance our understand-
ing of the in-depth mechanism of catalysis of deubiquitina-
tion and substrate specificity. As more missense mutations 
are described on DUBs in relation to tumorigenesis and 
various diseases, the physiological relevance of individual 
DUB and important mutation sites need to be validated by 
disease animal model. While a few DUB small molecule 
inhibitors shed light on anti-cancer therapy, more efforts 
are needed in drug development. Given our explored 
impact of DUBs in regulating DNA damage response and 
repair, it is important to determine the synergistic role of 
DUBs with current DNA damaging drugs in radiosensiti-
zation or chemosensitization of anti-cancer therapy.
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